Diarrhea, Immunosuppression
Conditions
Keywords
Diarrhea, Immunosuppression, Post-transplantation, Octreotide, Mycophenolate Mofetil, Fecal Calprotectin
Brief summary
Prospective, observational pilot study of ten post-transplant patients presenting with diarrhea while taking Mycophenolate Mofetil (MMF). These patients will undergo a standard workup to confirm MMF induced diarrhea. A stool fecal calprotectin will be measured to determine if it may be helpful in confirming the diagnosis of MMF associated diarrhea. Once the diagnosis is confirmed, the patients will then be treated with a short course of subcutaneous Octreotide which has been shown to cure this type of diarrhea.
Interventions
DRUGOctreotide Acetate
Octreotide 100mcg SC q12h for 5 days
Sponsors
University Health Network, Toronto
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Male and female patients between the ages of 18 and 75 years old who are solid organ transplant recipients followed at Toronto General Hospital on MMF referred to gastroenterology for diarrhea.
Exclusion criteria
1. Subjects with a known history of IBD or GVHD of the bowel. 2. Any subject receiving Octreotide for another indication. 3. Any patient unable to undergo endoscopy. 4. Any patient with a contraindication to Octreotide therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measurement of Fecal Calprotectin levels patients with diarrhea on MMF | 3 months |
Secondary
| Measure | Time frame |
|---|---|
| Treatment of patients with MMF induced diarrhea with Octreotide | 5 days |
Countries
Canada
Contacts
Primary ContactFlavio Habal, MD
Outcome results
None listed